Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study (Q59624425)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

title

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

7

Byron J Hoogwerf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

5

Sylvia K Shenouda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Michael Nauck

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Thomas Forst

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Wayne H-H Sheu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Cory R Heilmann

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Aijun Gao

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Marilyn K Boardman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Mark Fineman

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Lisa Porter

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Guntram Schernthaner

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

language of work or name

English

0 references

publication date

7 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

381

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

117-124

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

9861

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

17 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Diabetes Medication Satisfaction Tool: a focus on treatment regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

The PHQ-8 as a measure of current depression in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961267-7

7 January 2021

10.1016/S0140-6736(12)61267-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141817%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference